Bristol-Myers Squibb (NYSE:BMY) Position Increased by Cwm LLC

Cwm LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 6.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 519,463 shares of the biopharmaceutical company’s stock after acquiring an additional 30,921 shares during the period. Cwm LLC’s holdings in Bristol-Myers Squibb were worth $28,170,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of BMY. Northwest Financial Advisors bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $27,000. Pacific Capital Wealth Advisors Inc. bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $34,000. Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $40,000. Wetzel Investment Advisors Inc. bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $40,000. Finally, Fairman Group LLC bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $42,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on BMY. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Finally, Barclays dropped their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $60.00.

View Our Latest Stock Report on Bristol-Myers Squibb

Bristol-Myers Squibb Price Performance

NYSE BMY traded down $0.16 during trading on Wednesday, reaching $40.81. 18,747,217 shares of the company traded hands, compared to its average volume of 14,438,554. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The stock’s 50 day moving average price is $44.08 and its two-hundred day moving average price is $48.61. The company has a market cap of $82.73 billion, a price-to-earnings ratio of -13.16, a P/E/G ratio of 13.87 and a beta of 0.43. Bristol-Myers Squibb has a 1-year low of $39.91 and a 1-year high of $66.38.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.05 EPS. As a group, analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.88%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.